Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000199257 | SCV000254519 | likely benign | Nephronophthisis | 2025-01-23 | criteria provided, single submitter | clinical testing | |
Prevention |
RCV000248910 | SCV000303402 | benign | not specified | criteria provided, single submitter | clinical testing | ||
Eurofins Ntd Llc |
RCV000248910 | SCV000705856 | likely benign | not specified | 2017-01-23 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002517296 | SCV003543586 | uncertain significance | Inborn genetic diseases | 2021-04-20 | criteria provided, single submitter | clinical testing | The c.2081A>G (p.Q694R) alteration is located in exon 20 (coding exon 20) of the NPHP1 gene. This alteration results from a A to G substitution at nucleotide position 2081, causing the glutamine (Q) at amino acid position 694 to be replaced by an arginine (R). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |